AnaptysBio, Inc. (ANAB)
NASDAQ: ANAB · Real-Time Price · USD
55.46
+0.07 (0.13%)
At close: Mar 31, 2026, 4:00 PM EDT
55.46
0.00 (0.00%)
After-hours: Mar 31, 2026, 4:20 PM EDT
AnaptysBio Revenue
In the year 2025, AnaptysBio had annual revenue of $234.60M with 157.01% growth. AnaptysBio had revenue of $108.25M in the quarter ending December 31, 2025, with 151.08% growth.
Revenue (ttm)
$234.60M
Revenue Growth
+157.01%
P/S Ratio
6.87
Revenue / Employee
$2,255,798
Employees
104
Market Cap
1.59B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 234.60M | 143.32M | 157.01% |
| Dec 31, 2024 | 91.28M | 74.12M | 432.03% |
| Dec 31, 2023 | 17.16M | 6.87M | 66.78% |
| Dec 31, 2022 | 10.29M | -52.89M | -83.72% |
| Dec 31, 2021 | 63.18M | -11.83M | -15.77% |
| Dec 31, 2020 | 75.00M | 67.00M | 837.50% |
| Dec 31, 2019 | 8.00M | 3.00M | 60.00% |
| Dec 31, 2018 | 5.00M | -5.00M | -50.00% |
| Dec 31, 2017 | 10.00M | -6.68M | -40.06% |
| Dec 31, 2016 | 16.68M | -887.00K | -5.05% |
| Dec 31, 2015 | 17.57M | 1.73M | 10.94% |
| Dec 31, 2014 | 15.84M | 10.36M | 188.86% |
| Dec 31, 2013 | 5.48M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Harmony Biosciences Holdings | 868.45M |
| Innoviva | 411.33M |
| Vericel | 276.26M |
| Nurix Therapeutics | 83.98M |
| Recursion Pharmaceuticals | 74.68M |
| Generate Biomedicines | 31.89M |
| Capricor Therapeutics | 11.13M |
| Oculis Holding AG | 1.51M |
ANAB News
- 4 days ago - Anaptys Board of Directors Approves Spin-Off of First Tracks Biotherapeutics - GlobeNewsWire
- 4 days ago - Anaptys Announces $100 Million Stock Repurchase Plan and Provides a Business Update - GlobeNewsWire
- 4 days ago - First Tracks Biotherapeutics, the Planned Spin-Off of Anaptys, Secures Commitments of $145 Million in Private Placement - GlobeNewsWire
- 4 weeks ago - Anaptys Provides Update on Business Separation and Announces Fourth Quarter and Full Year 2025 Financial Results - GlobeNewsWire
- 4 weeks ago - Vanda Pharmaceuticals Announces FDA Acceptance of Biologics License Application Filing for Imsidolimab for the Treatment of Generalized Pustular Psoriasis - PRNewsWire
- 7 weeks ago - Anaptys Announces Participation at Upcoming Investor Conferences - GlobeNewsWire
- 2 months ago - AnaptysBio seeks partial dismissal in GSK oncology unit dispute over drug royalty - Reuters
- 2 months ago - Anaptys Files Motion to Dismiss Tesaro's Claim of Anticipatory Breach of Contract in Ongoing Litigation Against Tesaro, a GSK subsidiary - GlobeNewsWire